17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J. Clin. Invest. 1992;89 (3):883-891.
99. Arron JR and Choi Y. Bone versus immune system. Nature. 2000;408 (6812):535-536.
100. Oursler MJ, Cortese C, Keeting P, Anderson MA, Bonde SK, Riggs BL and Spelsberg TC. Modulation of transforming growth factor-beta production in normal human osteoblast-like cells by 17 beta-estradiol and parathyroid hormone.
Endocrinology. 1991;129 (6):3313-3320.
101. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, Tanaka S, Kodama T, Akira S, Iwakura Y, Cua DJ and Takayanagi H. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction.
J. Exp. Med. 2006;203 (12):2673-2682.
102. Kodama Y, Takeuchi Y, Suzawa M, Fukumoto S, Murayama H, Yamato H, Fujita T, Kurokawa T and Matsumoto T. Reduced Expression of Interleukin-11 in Bone Marrow Stromal Cells of Senescence-Accelerated Mice (SAMP6): Relationship to Osteopenia with Enhanced Adipogenesis. J Bone Miner Res. 1998;13 (9):1370-1377.
103. Girasole G, Passeri G, Jilka RL and Manolagas SC. Interleukin-11: a new cytokine critical for osteoclast development. J. Clin. Invest. 1994;93 (4):1516-1524.
104. Koga T, Matsui Y, Asagiri M, Kodama T, de Crombrugghe B, Nakashima K and Takayanagi H. NFAT and Osterix cooperatively regulate bone formation. Nat. Med.
2005;11 (8):880-885.
105. Sun L, Blair HC, Peng Y, Zaidi N, Adebanjo OA, Wu XB, Wu XY, Iqbal J, Epstein S, Abe E, Moonga BS and Zaidi M. Calcineurin regulates bone formation by the
osteoblast. Proc. Natl. Acad. Sci. U.S.A. 2005;102 (47):17130-17135.
106. Winslow MM, Pan M, Starbuck M, Gallo EM, DengL, Karsenty G and Crabtree GR.
Calcineurin/NFAT signaling in osteoblasts regulates bone mass. Dev. Cell. 2006;10 (6):771-782.
107. Löwik CW, van der Pluijm G, Bloys H, Hoekman K, Bijvoet OL, Aarden LA and
12
Papapoulos SE. Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis. Biochem. Biophys. Res. Commun. 1989;162 (3):1546-1552.
108. Allen DL, Uyenishi JJ, Cleary AS, Mehan RS, Lindsay SF and Reed JM.
Calcineurin activates interleukin-6 transcription in mouse skeletal muscle in vivo and in C2C12 myotubes in vitro. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2010;298 (1):R198-210.
109. Al-Humidan A, Ralston SH, Hughes DE, Chapman K, Aarden L, Russell RG and Gowen M. Interleukin-6 does not stimulate bone resorption in neonatal mouse calvariae. J Bone Miner Res. 2009;6 (1):3-8.
110. Ishimi Y, Miyaura C, Jin CH, Akatsu T, Abe E, Nakamura Y, Yamaguchi A, Yoshiki S, Matsuda T and Hirano T. IL-6 is produced by osteoblasts and induces bone
resorption. J. Immunol. 1990;145 (10):3297-3303.
111. Liu X, Kirschenbaum A, Yao S and Levine AC. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system. Endocrinology. 2005;146 (4):1991-1998.
112. Palmqvist P, Persson E, Conaway HH and Lerner UH. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J. Immunol. 2002;169 (6):3353-3362.
113. Whyte MP and Mumm S. Heritable disorders of the RANKL/OPG/RANK signaling pathway. J Musculoskelet Neuronal Interact. 2004;4 (3):254-267.
114. Guise TA and Mundy GR. Cancer and bone. Endocr. Rev. 1998;19 (1):18-54.
115. Yamamoto T, Ozono K, Kasayama S, Yoh K, Hiroshima K, Takagi M, Matsumoto S, Michigami T, Yamaoka K, Kishimoto T and Okada S. Increased IL-6-production by cells isolated from the fibrous bone dysplasia tissues in patients with McCune-Albright syndrome. J. Clin. Invest. 1996;98 (1):30-35.
116. Reddy SV, Takahashi S, Dallas M, Williams R, Neckers L and Roodman GD.
13
Interleukin-6 antisense deoxyoligonucleotides inhibit bone resorption by giant cells from human giant cell tumors of bone. J Bone Miner Res. 2009;9 (5):753-757.
117. Devlin RD, Bone HG and Roodman GD. Interleukin-6: a potential mediator of the massive osteolysis in patients with Gorham-Stout disease. J. Clin. Endocrinol. Metab.
1996;81 (5):1893-1897.
118. Boulton TG, Stahl N and Yancopoulos GD. Ciliary neurotrophic factor/leukemia inhibitory factor/interleukin 6/oncostatin M family of cytokines induces tyrosine phosphorylation of a common set of proteins overlapping those induced by other cytokines and growth factors. J. Biol. Chem. 1994;269 (15):11648-11655.
119. Miyaura C, Kusano K, Masuzawa T, Chaki O, Onoe Y, Aoyagi M, Sasaki T, Tamura T, Koishihara Y and Ohsugi Y. Endogenous bone-resorbing factors in estrogen deficiency: cooperative effects of IL-1 and IL-6. J. Bone Miner. Res. 1995;10 (9):1365-1373.
120. Cheleuitte D, Mizuno S and Glowacki J. In vitro secretion of cytokines by human bone marrow: effects of age and estrogen status. J. Clin. Endocrinol. Metab. 1998;83 (6):2043-2051.
121. Kawasaki K, Gao YH, Yokose S, Kaji Y, Nakamura T, Suda T, Yoshida K, Taga T, Kishimoto T, Kataoka H, Yuasa T, Norimatsu H and Yamaguchi A. Osteoclasts are present in gp130-deficient mice. Endocrinology. 1997;138 (11):4959-4965.
122. Walsh MC, Kim N, Kadono Y, Rho J, Lee SY, Lorenzo J and Choi Y.
Osteoimmunology: interplay between the immune system and bone metabolism. Annu.
Rev. Immunol. 2006;24:33-63.
123. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat. Rev. Immunol. 2007;7 (4):292-304.
124. Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000;289 (5484):1504-1508.
125. Wei S, Kitaura H, Zhou P, Ross FP and Teitelbaum SL. IL-1 mediates TNF-induced osteoclastogenesis. J. Clin. Invest. 2005;115 (2):282-290.
126. Kitaura H, Zhou P, Kim H, Novack DV, Ross FP and Teitelbaum SL. M-CSF
14
mediates TNF-induced inflammatory osteolysis. J. Clin. Invest. 2005;115 (12):3418-3427.
127. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Morinaga T, Higashio K, Martin TJ and Suda T. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J. Exp. Med. 2000;191 (2):275-286.
128 Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, McCabe S, Elliott R, Scully S, Van G, Kaufman S, Juan SC, Sun Y, Tarpley J and Martin L, Christensen K, McCabe J, Kostenuik P, Hsu H, Fletcher F, Dunstan CR, Lacey DL, Boyle WJ. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. U.S.A. 2000;97 (4):1566-1571.
129. Gilbert L, He X, Farmer P, Boden S, Kozlowski M, Rubin J and Nanes MS.
Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology.
2000;141 (11):3956-3964.
130 Centrella M, McCarthy TL and Canalis E. Tumor necrosis factor-alpha inhibits collagen synthesis and alkaline phosphatase activity independently of its effect on deoxyribonucleic acid synthesis in osteoblast-enriched bone cell cultures.
Endocrinology. 1988;123 (3):1442-1448.
131. Smith DD, Gowen M and Mundy GR. Effects of interferon-gamma and other cytokines on collagen synthesis in fetal rat bone cultures. Endocrinology. 1987;120 (6):2494-2499.
132. Tashjian AH, Voelkel EF, Lloyd W, Derynck R, Winkler ME and Levine L. Actions of growth factors on plasma calcium. Epidermal growth factor and human transforming growth factor-alpha cause elevation of plasma calcium in mice. J. Clin. Invest. 1986;78 (5):1405-1409.
133. Raisz LG and Niemann I. Effect of phosphate, calcium and magnesium on bone resorption and hormonal responses in tissue culture. Endocrinology. 1969;85
(3):446-452.
134. Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M,
15
Mineau F and Pelletier JP. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J.
Immunol. 1998;160 (7):3513-3521.
135. Fossiez F, Banchereau J, Murray R, Van Kooten C, Garrone P and Lebecque S.
Interleukin-17. Int. Rev. Immunol. 1998;16 (5-6):541-551.
136. Chabaud M, Fossiez F, Taupin JL and Miossec P. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J. Immunol. 1998;161 (1):409-414.
137. Starnes T, Robertson MJ, Sledge G, Kelich S, Nakshatri H, Broxmeyer HE and Hromas R. Cutting edge: IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production.
J. Immunol. 2001;167 (8):4137-4140.
138. Kawaguchi M, Onuchic LF, Li XD, Essayan DM, Schroeder J, Xiao HQ, Liu MC Krishnaswamy G, Germino G and Huang SK. Identification of a novel cytokine, ML-1, and its expression in subjects with asthma. J. Immunol. 2001;167 (8):4430-4435.
139. Watanabe K, Tanaka Y, Morimoto I, Yahata K, Zeki K, Fujihira T, Yamashita U and Eto S. Interleukin-4 as a potent inhibitor of bone resorption. Biochemical and Biophysical Research Communications. 1990;172 (3):1035-1041.
140. Howard M, Farrar J, Hilfiker M, Johnson B, Takatsu K, Hamaoka T and Paul WE.
Identification of a T cell-derived b cell growth factor distinct from interleukin 2. J. Exp.
Med. 1982;155 (3):914-923.
141. Boulay JL and Paul WE. The interleukin-4-related lymphokines and their binding to hematopoietin receptors. Journal of Biological Chemistry. 1992;267 (29):20525 -20528.
142. Mundy GR, Ibbotson KJ and D’Souza SM, Simpson EL, Jacobs JW, Martin TJ.
The hypercalcemia of cancer. Clinical implications and pathogenic mechanisms. N.
Engl. J. Med. 1984;310 (26):1718-1727.
143. Takayanagi H, Ogasawara K, Hida S Chiba T, Murata S, Murata S, Sato K, Takaoka
A, Yokochi T, Oda H, Tanaka K, Nakamura K and Taniguchi T. T-cell-mediated
regulation of osteoclastogenesis by signalling cross-talk between RANKL and
16
IFN-gamma. Nature. 2000;408 (6812):600-605.
144. O'Brien EA, Williams JH and Marshall MJ. Osteoprotegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria. Biochem. Biophys. Res.
Commun. 2000;274 (2):281-290.
145. Rodan GA and Martin TJ. Role of osteoblasts in hormonal control of bone resorption--a hypothesis. Calcif. Tissue Int. 1981;33 (4):349-351.
146. Burgess TL, Qian Y, Kaufman S, Ring BD, Van G, Capparelli C, Kelley M, Hsu H, Boyle WJ, Dunstan CR, Hu S and Lacey DL. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J. Cell Biol. 1999;145 (3):527-538.
147. Lacey DL, Tan HL, Lu J, Kaufman S, Van G and Qiu W, Rattan A, Scully S, Fletcher F, Juan T, Kelley M, Burgess TL, Boyle WJ, Polverino AJ. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am. J. Pathol.
2000;157 (2):435-448.
148. O'Brien EA, Williams JH and Marshall MJ. Osteoprotegerin is produced when prostaglandin synthesis is inhibited causing osteoclasts to detach from the surface of mouse parietal bone and attach to the endocranial membrane. Bone. 2001;28
(2):208-214.
149. Mosekilde L, Søgaard CH, Danielsen CC and Tørring O. The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biomechanical testing: a comparison study between hPTH-(1-34) and hPTH-(1-84). Endocrinology. 1991;129 (1):421-428.
150. Capparelli C, Morony S, Warmington K, Adamu S, Lacey D, Dunstan CR, Stouch B, Martin S and Kostenuik PJ. Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and
pharmacokinetic analysis in rats. J. Bone Miner. Res. 2003;18 (5):852-858.
151. Vanderkerken K, De Leenheer E, Shipman C, Asosingh K, Willems A, Camp BV and Croucher P. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res. 2003;63 (2):287-289.
152. Redlich K, Hayer S, Maier A, Dunstan CR, Tohidast-Akrad M, Lang S, Türk B,
Pietschmann P, Woloszczuk W, Haralambous S, Kollias G, Steiner G, Smolen JS and
17
Schett G. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum. 2002;46 (3):785-792.
153. Kostenuik PJ, Bolon B, Morony S, Daris M, Geng Z, Carter C and Sheng J. Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice. Bone. 2004;34 (4):656-664.
154. Byrne FR, Morony S, Warmington K, Geng Z, Brown HL, Flores SA, Fiorino M, Yin SL, Hill D, Porkess V, Duryea D, Pretorius JK, Adamu S, Manoukian R, Manuokian R, Danilenko DM, Sarosi I, Lacey DL, Kostenuik PJ and Senaldi G.CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin. Gut. 2005;54 (1):78-86.
155. Allen MR and Bloomfield SA. Hindlimb unloading has a greater effect on cortical compared with cancellous bone in mature female rats. J. Appl. Physiol. 2003;94 (2):642-650.
156. Kodama Y, Nakayama K, Fuse H, Fukumoto S, Kawahara H, Takahashi H, Kurokawa T, Sekiguchi C, Nakamura T and Matsumoto T. Inhibition of bone resorption by pamidronate cannot restore normal gain in cortical bone mass and strength in tail-suspended rapidly growing rats. J. Bone Miner. Res. 1997;12 (7):1058-1067.
157. Takayanagi H. Mechanistic insight into osteoclast differentiation in osteoimmunology. J. Mol. Med. 2005;83 (3):170-179.
158. Mao D, Epple H, Uthgenannt B, Novack DV and Faccio R. PLCgamma2 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2. J. Clin. Invest.
2006;116 (11):2869-2879.
159. Miyao M, Morita H, Hosoi T, Kurihara H, Inoue S, Hoshino S, Shiraki M, Yazaki Y and Ouchi Y. Association of methylenetetrahydrofolate reductase (MTHFR) polymorphism with bone mineral density in postmenopausal Japanese women. Calcif.
Tissue Int. 2000;66 (3):190-194.
160. Kleinbaum DG, Kupper LL and Muller KE. 1998 Applied regeneration analysis and other multivariate methods. 2nd ed., PWS-Kent, Boston, pp. 299-301.
161. Kim OJ, Lee JH, Choi JK, Oh SH, Hong SH, Oh D and Kim NK. Association
between tumor necrosis factor-alpha (-308G→A and -238G→A) polymorphisms and
18
homocysteine levels in patients with ischemic strokes and silent brain infarctions.
Cerebrovasc. Dis. 2010;30 (5):483-490.
162. Seiderer J, Elben I, Diegelmann J, Glas J, Stallhofer J, Tillack C, Pfennig S, Jürgens M, Schmechel S, Konrad A, Göke B, Ochsenkühn T, Müller-Myhsok B, Lohse P and Brand S. Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn’s disease and analysis of the IL17F p.His161Arg polymorphism in IBD. Inflamm. Bowel Dis. 2008;14 (4):437-445.
163. Kawaguchi M, Takahashi D, Hizawa N, Suzuki S, Matsukura S, Kokubu F, Maeda Y, Fukui Y, Konno S, Huang SK, Nishimura M and Adachi M. IL-17F sequence variant (His161Arg) is associated with protection against asthma and antagonizes wild-type IL-17F activity. J. Allergy Clin. Immunol. 2006;117 (4):795-801.
164. Lario S, Iñigo P, Campistol JM, Poch E, Rivera F and Oppenheimer F. Restriction enzyme-based method for transforming growth factor-beta (1) genotyping:
nonisotopic detection of polymorphisms in codons 10 and 25 and the 5’-flanking region. Clin. Chem. 1999;45 (8 Pt 1):1290-1292.
165. Jørgensen HL, Kusk P, Madsen B, Fenger M and Lauritzen JB. Serum
osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios. J. Bone Miner.
Metab. 2004;22 (2):132-138.
166. Orimo H, Sugioka Y, Fukunaga M, Yoshiteru M, Hotokebuchi T, Gorai I, Nakamura T, Kushida K, Tanaka H, Ikai T and Oh-hashi Y. Diagnostic criteria for primary osteoporosis, J. Bone Miner. Metab. 1998;16:139-150.
167. Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-Hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T and Kishimoto H. Diagnostic criteria for primary osteoporosis: year 2000 revision. J. Bone Miner. Metab. 2001;19 (6):331-337.
168. Ilich JZ, Badenhop NE and Matkovic V. Primary prevention of osteoporosis:
pediatric approach to disease of the elderly. Womens Health Issues. 1996;6
(4):194-203.
19
169. Carrié Fässler AL and Bonjour JP. Osteoporosis as a pediatric problem. Pediatr.
Clin. North Am. 1995;42 (4):811-824.
170. Bachrach LK. Acquisition of optimal bone mass in childhood and adolescence.
Trends Endocrinol. Metab. 2001;12 (1):22-28.
171. Meumier PJ. 1998 Osteoporosis: diagnosis and management edited by Bone remodeling and mechanisms of bone loss in osteoporosis. MARTINDUNITZ, London, pp. 17-34.
172. Moffett SP, Zmuda JM, Oakley JI, Beck TJ, Cauley JA, Stone KL, Lui LY, Ensrud KE, Hillier TA, Hochberg MC, Morin P, Peltz G, Greene D and Cummings SR. Tumor necrosis factor-alpha polymorphism, bone strength phenotypes, and the risk of fracture in older women. J. Clin. Endocrinol. Metab. 2005;90 (6):3491-3497.
173. Roberts AB, Sporn MB. 1990 The transforming growth factor-βs. in: M.B. Sporn, A.B. Roberts (Eds.), Peptide growth factors and their receptors, partI. Springer-Verlag, Berlin, pp. 419-472.
174. Yamada Y. Association of a Leu(10)-->Pro polymorphism of the transforming growth factor-beta1 with genetic susceptibility to osteoporosis and spinal
osteoarthritis. Mech. Ageing Dev. 2000;116 (2-3):113-123.
175. Langdahl BL, Carstens M, Stenkjaer L and Eriksen EF. Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures. J. Bone Miner. Res.
2002;17 (7):1245-1255.
176. Zajícková K, Zemanová A, Hill M and Zofková I. Is A163G polymorphism in the osteoprotegerin gene associated with heel velocity of sound in postmenopausal women? Physiol Res. 2008;57 Suppl 1:S153-157.
177. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, Andria G, Boers GH, Bromberg IL and Cerone R. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am. J. Hum. Genet. 1985;37 (1):1-31.
178. Saito M and Marumo K. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus.
Osteoporos Int. 2010;21 (2):195-214.
179. Poli V, Balena R, Fattori E, Markatos A, Yamamoto M, Tanaka H, Ciliberto G,
20
Rodan GA and Costantini F. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 1994;13 (5):1189-1196.
180. Ferrari SL, Garnero P, Emond S, Montgomery H, Humphries SE and Greenspan SL. A functional polymorphic variant in the interleukin-6 gene promoter associated with low bone resorption in postmenopausal women. Arthritis Rheum. 2001;44 (1):196-201.
181. Yamada Y, Ando F, Niino N and Shimokata H. Association of polymorphisms of interleukin-6, osteocalcin, and vitamin D receptor genes, alone or in combination, with bone mineral density in community-dwelling Japanese women and men. J. Clin.
Endocrinol. Metab. 2003;88 (7):3372–3378.
182. Liao W-C, Lin J-T, Wu C-Y, Huang S-P, Lin M-T, Wu AS-H, Huang Y-J and Wu MS. Serum interleukin-6 level but not genotype predicts survival after resection in stages II and III gastric carcinoma. Clin. Cancer Res. 2008;14 (2):428-434.
183. Suresh S. A New Paradigm in Autoimmunity-Role In Periodontal Disease. Indian Journal Of Dental Advancements. 2011;03:583-586.
184. Kawaguchi M, Fujita J, Kokubu F, Huang S-K, Homma T, Matsukura S, Adachi M and Hizawa N. IL-17F-induced IL-11 release in bronchial epithelial cells via MSK1-CREB pathway. Am. J. Physiol. Lung Cell Mol. Physiol. 2009;296 (5):L804-810.
185. Kido S, Kuriwaka-Kido R, Imamura T, Ito Y, Inoue D and Matsumoto T. Mechanical stress induces Interleukin-11 expression to stimulate osteoblast differentiation. Bone.
2009;45 (6):1125-1132.
186. Soufi M, Schoppet M, Sattler AM, Herzum M, Maisch B, Hofbauer LC and Schaefer JR. Osteoprotegerin gene polymorphisms in men with coronary artery disease. J. Clin. Endocrinol. Metab. 2004;89 (8):3764-3768.
187. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J and Rozen R. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations.
Circulation. 1996;93 (1):7-9.
188. Jørgensen HL, Madsen JS, Madsen B, Saleh MMA, Abrahamsen B, Fenger M and
Lauritzen JB. Association of a common allelic polymorphism (C677T) in the methylene
21
tetrahydrofolate reductase gene with a reduced risk of osteoporotic fractures. A case control study in Danish postmenopausal women. Calcif. Tissue Int. 2002;71 (5):386–392.
189. Li M, Lau EMC and Woo J. Methylenetetrahydrofolate reductase polymorphism (MTHFR C677T) and bone mineral density in Chinese men and women. Bone. 2004;35 (6):1369–1374.
190. van Meurs JBJ, Dhonukshe-Rutten RAM, Pluijm SMF van der Klift M, de Jonge R, Lindemans J, de Groot LCPGM, Hofman A, Witteman JCM, van Leeuwen JPTM, Breteler MMB, Lips P, Pols HAP and Uitterlinden AG. Homocysteine levels and the risk of osteoporotic fracture. N. Engl. J. Med. 2004;350 (20):2033–2041.
191. Oishi Y, Shinoda S, Watanabe Y, Naka and M, Fuke, Y. A pilot study of genetic polymorphisms commonly associated with osteoporosis and bone mineral density in young Japanese women, Jpn J. Prev. Med. 2012; 7:11-15.
192. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A and Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the
differentiation of interleukin 17-producing human T helper cells. Nat. Immunol. 2007;8 (9):942-949.
193. Hofbauer LC, Hicok KC, Schroeder MJ Harris SA, Robinson JA and Khosla S.
Development and characterization of a conditionally immortalized human osteoblastic cell line stably transfected with the human androgen receptor gene. J. Cell Biochem.
1997;66 (4):542-551.
194. Caputo JL. Biosafety procedures in cell culture. J. Tissue. Cult. Meth. 1988;11:
223-227.
195. Burstone MS. Histochemical comparison of naphthol AS-phosphates for the demonstration of phosphatases. J. Natl. Cancer Inst. 1958;20 (3):601-615.
196. Seriwatanachai D, Charoenphandhu N, Suthiphongchai T and Krishnamra N.
Prolactin decreases the expression ratio of receptor activator of nuclear factor
kappaB ligand/osteoprotegerin in human fetal osteoblast cells. Cell Biol. Int. 2008;32
(9):1126-1135.
22
197. von Kossa J. Ueber die im organismus kunstlich erzeugbaren verkalkungen. Beit Path Anat 1901;29:163.
198 Burston MS. Histochemical demonstration of acid phosphatases with naphthol AS-phosphates. J. Natl. Cancer Inst. 1958;21 (3):523-539.
199. Udagawa N, Kotake S, Kamatani N, Takahashi N and Suda T. The molecular mechanism of osteoclastogenesis in rheumatoid arthritis. Arthritis Res. 2002;4 (5):281-289.
200. Walsh NC, Crotti TN, Goldring SR and Gravallese EM. Rheumatic diseases: the effects of inflammation on bone. Immunol. Rev. 2005;208:228-251.
201. Pap T, Müller-Ladner U, Gay RE and Gay S. Fibroblast biology. Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res. 2000;2
(5):361-367.
202. Konttinen YT, Li TF, Hukkanen M, Ma J, Xu JW and Virtanen I. Fibroblast biology.
Signals targeting the synovial fibroblast in arthritis. Arthritis Res. 2000;2 (5):348-355.
203. Neumann E, Gay S and Müller-Ladner U. The RANK/RANKL/osteoprotegerin system in rheumatoid arthritis: new insights from animal models. Arthritis Rheum.
2005;52 (10):2960-2967.
204. Ｉshibashi S and Koshihara Y. Stimulation of accumulation of extracellular matrix by interleukin 4 in human osteoblast-like cells and involvement of type Ⅳ collagen.
Japan. J. Bone Metab. 1995;13: 260.
205. Yasukawa H, Sasaki A and Yoshimura A. Negative regulation of cytokine signaling pathways. Annu. Rev. Immunol. 2000;18:143–164.
206. Alexander WS. Suppressors of cytokine signalling (SOCS) in the immune system.
Nat. Rev. Immunol. 2002;2 (6):410–416.
207. Greenhalgh CJ, Miller ME, Hilton DJ and Lund PK. Suppressors of cytokine signaling: Relevance to gastrointestinal function and disease. Gastroenterology.
2002;123 (6):2064–2081.
208. Kawaguchi M, Kokubu F, Odaka M, Watanabe S, Suzuki S, Ieki K, Matsukura S,
Kurokawa M, Adachi M and Huang S-K. Induction of granulocyte-macrophage
23
colony-stimulating factor by a new cytokine, ML-1 (IL-17F), via Raf I-MEK-ERK pathway. J. Allergy Clin. Immunol. 2004;114 (2):444–450.
209. Kawaguchi M, Kokubu F, Huang S-K, Homma T, Odaka M, Watanabe S, Suzuki S, Ieki K, Matsukura S, Kurokawa M and Adachi M. The IL-17F signaling pathway is involved in the induction of IFN-gamma-inducible protein 10 in bronchial epithelial cells. J. Allergy Clin. Immunol. 2007;119 (6):1408–1414.
210. Rong Z, Cheng L, Ren Y, Li Z, Li Y, Li X, Li H, Fu X-Y and Chang Z.
Interleukin-17F signaling requires ubiquitination of interleukin-17 receptor via TRAF6.
Cell. Signal. 2007;19 (7):1514–1520.
211. Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H and Sakai H. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem. Biophys. Res. Commun. 2000;275 (3):768–775.
212. Yamaguchi Y, Fujio K, Shoda ,Okamoto A, Tsuno N H, Takahashi K and Yamamoto K. IL-17B and IL-17C are associated with TNF-alpha production and contribute to the exacerbation of inflammatory arthritis. J. Immunol. 2007;179 (10):7128–7136.
213. Kawaguchi M, Onuchic LF, Li XD, Essayan DM, Schroeder J, Xiao HQ, Liu MC, Krishnaswamy G, Germino G and Huang SK. Identification of a novel cytokine, ML-1, and its expression in subjects with asthma. J. Immunol. 2001;167 (8):4430–4435.
214. Erices A, Conget P, Rojas C and Minguell JJ. Gp130 activation by soluble interleukin-6 receptor/interleukin-6 enhances osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells. Exp. Cell Res. 2002;280 (1):24–32.
215. Rose-John S, Scheller J, Elson G and Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J. Leukoc. Biol. 2006;80 (2):227–236.
216. Bendixen AC, Shevde NK, Dienger KM Willson TM, Funk CD and Pike JW. IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1. Proc. Natl. Acad. Sci. U.S.A.
2001;98 (5):2443-2448.
217. Kamel Mohamed SG, Sugiyama E, Shinoda K, Hounoki H, Taki H, Maruyama M,
24
Miyahara T and Kobayashi M. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: A possible mechanism for downregulation of osteoclastogenesis.
Biochemical and Biophysical Research Communications. 2005;329 (3):839-845.
218. Mangashetti LS, Khapli SM and Wani MR. IL-4 inhibits bone-resorbing activity of mature osteoclasts by affecting NF-kappa B and Ca2+ signaling. J. Immunol. 2005;175 (2):917-925.
219. Moreno JL, Kaczmarek M, Keegan AD and Tondravi M. IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: irreversible inhibition of the differentiation program activated by RANKL.
Blood. 2003;102 (3):1078-1086.
220. Yamada A, Takami M, Kawawa T, Yasuhara R, Zhao B, Mochizuki A, Miyamoto Y, Eto T, Yasuda H, Nakamichi Y, Kim N, Katagiri T, Suda T and Kamijo R. Interleukin-4 inhibition of osteoclast differentiation is stronger than that of interleukin-13 and they are equivalent for induction of osteoprotegerin production from osteoblasts.
Immunology. 2007;120 (4):573-579.
221. Vescovi JD, Scheid JL, Hontscharuk R and De Souza MJ. Cognitive dietary restraint: Impact on bone, menstrual and metabolic status in young women. Physiology
& Behavior. 2008;95 (1-2):48-55.
222. Nickols-Richardson SM, Beiseigel JM and Gwazdauskas FC. Eating Restraint Is Negatively Associated with Biomarkers of Bone Turnover but Not Measurements of Bone Mineral Density in Young Women. Journal of the American Dietetic Association.
2006;106 (7):1095-1101.
223. Liu Y-Z, Liu Y-J, Recker RR and Deng H-W. Molecular studies of identification of genes for osteoporosis: the 2002 update. J. Endocrinol. 2003;177 (2):147-196.
224. Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2 (8):e124.
225. Shen H, Liu Y, Liu P, Recker RR and Deng H-W. Nonreplication in genetic studies
of complex diseases--lessons learned from studies of osteoporosis and tentative
remedies. J. Bone Miner. Res. 2005;20 (3):365-376.
ドキュメント内
The Effects of Immune Cytokines on Bone Mineral Density and
(ページ 110-126)